Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis Source: Eur Respir J 2001; 18: 43S-55S Year: 2001
Difference in immunological aspects of inflammation in idiopathic pulmonary fibrosis (IPF) and exogenous toxic alveolitis (ETA) Source: Eur Respir J 2003; 22: Suppl. 45, 121s Year: 2003
Macrophage derived inflammatory mediators and thoracic HRCT scoring in scleroderma fibrosing alveolitis Source: Eur Respir J 2002; 20: Suppl. 38, 227s Year: 2002
MMPs in BAL from patients with scleroderma fibrosing alveolitis Source: Eur Respir J 2006; 28: Suppl. 50, 564s Year: 2006
Exhaled 8-isoprostane as a noninvasive marker of oxidative stress in patients with cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis Source: Eur Respir J 2001; 18: Suppl. 33, 408s Year: 2001
Surfactant protein A in chronic extrinsic allergic alveolitis Source: Eur Respir J 2012; 39: 1543-1544 Year: 2012
Cytokine regulation in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis: clinicomorphological study Source: Eur Respir J 2001; 18: Suppl. 33, 107s Year: 2001
Distinguishing fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis Source: International Congress 2019 – Lungs in the fog Year: 2019
Sputum eosinophilia in cryptogenic fibrosing alveolitis Source: Eur Respir J 2003; 22: Suppl. 45, 227s Year: 2003
Cytokine gene polymorphisms in fibrosing alveolitis in rheumatoid arthritis and idiopathic pulmonary fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 1s Year: 2001
Small airways impairment and air-trapping distinguish chronic hypersensitivity pneumonitis (CHP) from idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical problems Year: 2017
Parameters of antioxidant protection in patients with cryptogenic fibrosing alveolitis Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007
Role of Wnt-1, Wnt-3 and MMP-7 in fibrotic response in extrinsic allergic alveolitis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015
Hemocoagulation and platelet aggregation disorders in patients with cryptogenic fibrosing alveolitis (CFA) Source: Eur Respir J 2002; 20: Suppl. 38, 226s Year: 2002
Clinical significance of morphological indexes of inflammation and sclerosis in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002
Induced sputum neutrophilia and increased neurotrophin levels in patients with cryptogenic fibrosing alveolitis Source: Eur Respir J 2002; 20: Suppl. 38, 173s Year: 2002
Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature Source: Eur Respir Rev 2012 21: 355-361 Year: 2012
Inhibition of local fibrinolysis differs between idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (f-NSIP) Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009
Clinical significance of different cytokines expression in lung tissue in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 313s Year: 2002
Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom? Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment Year: 2006